FAMEGLOW (SEHK: 03774) has officially transitioned from the Growth Enterprise Market (GEM) to the Main Board of the Hong Kong Stock Exchange, with its stock code changing from 08603 to 03774.

This medical aesthetics service provider, which initially listed on the GEM in October 2018, has now entered the primary tier of the Hong Kong capital market after nearly eight years of development.

On its first day of trading on the Main Board, the company's shares opened higher and maintained strong momentum.

The stock opened at HK$14.5 and closed at HK$16, giving the company a market capitalisation of approximately HK$13.1 billion, reflecting positive market expectations for improved liquidity and a potential re-rating following the transfer.

Against the backdrop of a simplified GEM transfer mechanism, the company's successful move to the Main Board highlights the exchange's supportive stance for qualifying GEM companies and serves as a comprehensive endorsement of the firm's corporate governance, business scale, and financial performance.

Notably, this transition coincides with a pivotal period as the company expands its "AI + anti-aging" business.

The stricter regulatory requirements and higher market threshold of the Main Board act as a authoritative validation of the company's operational strength.

Furthermore, the increased liquidity from institutional and international investors is expected to help the company broaden its financing channels, providing more substantial capital resources for its next phase of expansion.

Business Overview and Growth Trajectory

Public information indicates that FAMEGLOW is a Hong Kong-based provider of medical aesthetic services.

Its business encompasses non-surgical medical aesthetics, traditional beauty services, and skincare product sales.

To date, the company operates 16 medical aesthetic centres located in key commercial districts across Hong Kong and Macau.

In recent years, the company has built a diverse multi-brand portfolio, covering various segments such as medical aesthetics, men's hair removal, laser skincare, hair care, and lifestyle beauty, effectively catering to consumers' increasingly varied needs.

Financial and Operational Performance

The past three years have marked a period of rapid expansion for the company.

Revenue for the fiscal years ending March 31, 2024, 2025, and 2026 was approximately HK$299 million, HK$435 million, and HK$590 million, respectively, representing a compound annual growth rate exceeding 40%.

Net profit also grew steadily from about HK$41 million to HK$55 million.

Concurrently, the active customer base nearly doubled, and the average spending per customer increased, indicating enhanced service quality and customer loyalty.

As of March 31, 2026, the company held cash and bank balances of around HK$110.7 million, with total assets of HK$259 million and total equity of HK$207.1 million, demonstrating robust financial health and ample cash reserves.

Future Strategy and AI Integration

Looking ahead, FAMEGLOW is strategically focusing on the emerging field of "AI + high-end biotech skincare".

In October 2025, the company established a joint venture with partners including a Japanese pharmaceutical firm and a Singaporean commercial biotech company, focusing on the R&D and sales of anti-aging products and solutions.

The JV has already launched the precision anti-aging brand "素肌源创".

Moving forward, the company plans to increase strategic investment in AI and high-end biotech skincare.

Leveraging an AI-powered anti-aging management solution developed by its commissioned R&D team, which incorporates licensed AI technology, the company aims to build a comprehensive service system covering skin monitoring, aging assessment, solution matching, and efficacy tracking.

This foundation positions the company to potentially collaborate with various industry partners to integrate clinical anti-aging technology, biological R&D capabilities, AI computing platforms, and commercial operational resources, creating a holistic industrial ecosystem.

Post-Listing Outlook

Following this milestone transfer, a key challenge for FAMEGLOW will be to effectively translate the enhanced brand recognition and capital advantages of a Main Board listing into tangible drivers for business growth.

Whether this "beauty tech + AI" company, which originated on the GEM, can continue its growth narrative on the Main Board stage remains a point of interest for investors.